Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
WALTHAM, Mass., Feb. 03, 2016 -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, President and COO of TESARO, will present at the Leerink Partners 5th Annual Global Healthcare Conference at the Waldorf Astoria in New York City on February 10, 2016 at 2:40 PM Eastern time.
A live webcast of this presentation will be accessible via the Investors page of the TESARO website at www.tesarobio.com. An archived replay of the webcast will be available on the Company’s website for 14 days following the conference.
About TESARO
TESARO, Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.
For additional information, please contact: Jennifer Davis 1.781.325.1116 [email protected]
